Hologic Inc (HOLX): Today's Featured Health Care Laggard

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

Hologic ( HOLX) pushed the Health Care sector lower today making it today's featured Health Care laggard. The sector as a whole closed the day down 0.4%. By the end of trading, Hologic fell 40 cents (-2.1%) to $18.68 on average volume. Throughout the day, two million shares of Hologic exchanged hands as compared to its average daily volume of 2.6 million shares. The stock ranged in price between $18.65-$19.17 after having opened the day at $19.11 as compared to the previous trading day's close of $19.08. Other companies within the Health Care sector that declined today were: Oxygen Biotherapeutics ( OXBT), down 13.6%, Biocryst Pharmaceuticals ( BCRX), down 12.2%, Delcath Systems ( DCTH), down 9.3%, and Globus Medical Inc Class A ( GMED), down 8.8%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Hologic Inc. develops, manufactures, and supplies diagnostic, medical imaging systems, and surgical products for the healthcare needs of women. The company operates in four segments: Breast Health, Diagnostics, GYN Surgical, and Skeletal Health. Hologic has a market cap of $5.07 billion and is part of the health services industry. Shares are up 8.5% year to date as of the close of trading on Friday. Currently there are 15 analysts that rate Hologic a buy, no analysts rate it a sell, and four rate it a hold.

TheStreet Ratings rates Hologic as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, increase in stock price during the past year and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and generally higher debt management risk.

On the positive front, Neuralstem ( CUR), up 19.2%, Cyclacel Pharmaceuticals ( CYCC), up 18.3%, Idera Pharmaceuticals ( IDRA), up 13.5%, and Alphatec Holdings ( ATEC), up 13.4%, were all gainers within the health care sector with Pharmacyclics Incorporated ( PCYC) being today's featured health care sector leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

Holiday Special: Subscribe to Action Alerts PLUS to see how Jim Cramer trades his $2.5 Million+ portfolio for 51% off the list price. Your first 14-days are FREE: Sign up today to get e-mail alerts before every trade.

null

More from Markets

NYSE Suspends Trading for Some Shares of Amazon, Alphabet

NYSE Suspends Trading for Some Shares of Amazon, Alphabet

Stocks Slide Amid a Rise in Bond Yields, Strong Earnings

Stocks Slide Amid a Rise in Bond Yields, Strong Earnings

Video: Jim Cramer Reveals Why He's Cautious on Stocks

Video: Jim Cramer Reveals Why He's Cautious on Stocks

Jim Cramer on Earnings: All Stories Aren't Equal

Jim Cramer on Earnings: All Stories Aren't Equal

4 Stocks Making Important Moves Wednesday

4 Stocks Making Important Moves Wednesday